TONGRENTANGCARE (02667) announced its interim results, with profits attributable to shareholders of the parent company amounting to 7.885 million yuan, a decrease of 26.53% year-on-year.
Tongrentang Medical and Health (02667) announced its mid-term results for 2026, with revenue of approximately 507 million yuan, a year-on-year decrease of 12.6%. Gross profit was about 91.7 million yuan, a year-on-year decrease of 10.8%. Profit attributable to owners of the parent company was 7.885 million yuan, a year-on-year decrease of 26.53%.
TONGRENTANGCARE (02667) announced its interim results for 2026, with revenue of approximately 507 million yuan, a decrease of 12.6% year-on-year. Gross profit was approximately 91.7 million yuan, a decrease of 10.8% year-on-year. The profit attributable to the company's shareholders was 7.885 million yuan, a decrease of 26.53% year-on-year.
The announcement stated that the year-on-year decrease in profit was primarily due to losses incurred during the initial operation of Shunyi Beijing Tongrentang Traditional Chinese Medicine Hospital, which opened in May 2026.
Related Articles
After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."
Electra Therapeutics (ETRA.US) has submitted an IPO application for the U.S. stock market, leveraging the current biotech IPO boom to advance the development of new drugs for immune diseases and cancer.
Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).
After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."
Electra Therapeutics (ETRA.US) has submitted an IPO application for the U.S. stock market, leveraging the current biotech IPO boom to advance the development of new drugs for immune diseases and cancer.
Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).
RECOMMEND
